Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMVP Health Care Syfovre Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Syfovre

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Syfovre (pegcetacoplan) administered under the Medicare Part B medical benefit. It applies to providers seeking coverage for members with geographic atrophy secondary to age-related macular degeneration.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Syfovre
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the AMD-related geographic atrophy diagnosis and required visual acuity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J2781Prior authorization code
    6 monthsInitial approval
    Up to 1 yearSubsequent approval
    ≥24 ETDRSVisual acuity threshold
    AMD-related GA

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered etiology

    Coverage Criteria

    Initial therapy

    Covered when ALL of the following are met:

    Initial Syfovre coverage

    • Prescriber and administration

      • Prescribed and administered by an ophthalmologist.
    • Qualifying diagnosis

      • Chart notes confirm the diagnosis of geographic atrophy secondary to age-related macular degeneration.
    • Visual acuity

      • Best-corrected visual acuity is at least 24 letters using Early Treatment Diabetic Retinopathy Study charts or has an approximate Snellen equivalent of 20/320.BCVA ≥24 ETDRS letters OR approximate Snellen equivalent of 20/320

    Continuation therapy

    Subsequent approval requires:

    Continuation of Syfovre coverage: Documentation of clinical benefit from therapy is required for subsequent approval.Documented clinical benefit

    Subsequent approvals will be for up to 1 year duration.

    Syfovre is not covered for members with ocular or periocular infections.

    Syfovre is not covered for members with active intraocular inflammation.

    Syfovre is not covered when the age, dosage, or frequency of use is outside FDA-approved package labeling.

    Syfovre is not covered for geographic atrophy secondary to a condition other than age-related macular degeneration, including Stargardt disease in either eye.

    Medical Benefit Coding

    Drugs Requiring Prior Authorization under the medical benefitHCPCS
    J2781Syfovre (pegcetacoplan) solution for injection
    Best-corrected visual acuity
    ETDRS thresholdAt least 24 letters using Early Treatment Diabetic Retinopathy Study (ETDRS) charts
    Approximate Snellen equivalent20/320

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Syfovre (pegcetacoplan) under the medical benefit. The medication must be prescribed and administered by an ophthalmologist, and related authorization and administration requirements must be met.

    • Medical benefit prior authorization is required before treatment.
    • Syfovre must be prescribed and administered by an ophthalmologist.
    Documentation Required

    Diagnosis and Visual Acuity Documentation

    Submit chart notes confirming geographic atrophy (GA) secondary to age-related macular degeneration (AMD), along with the member’s best-corrected visual acuity (BCVA).

    • Diagnosis: GA secondary to AMD.
    • BCVA must be ≥24 letters using Early Treatment Diabetic Retinopathy Study (ETDRS) charts or approximately 20/320 on the Snellen scale.

    Therapy Background

    Syfovre (pegcetacoplan) is a parenteral complement C3 inhibitor administered by intravitreal injection. It is FDA approved for geographic atrophy secondary to the dry advanced form of age-related macular degeneration, an irreversible eye disease.

    Policy Definitions

    Geographic atrophy (GA)
    Covered conditionGeographic atrophy (GA) secondary to the dry advanced form of age-related macular degeneration (AMD)
    Disease descriptionGA is an irreversible eye disease
    FDA-approved treatment indicationSyfovre is FDA approved for the treatment of GA secondary to dry advanced AMD
    Best-corrected visual acuity (BCVA)
    Measurement methodBest-corrected visual acuity (BCVA) is measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts
    Policy thresholdAt least 24 letters
    Approximate Snellen equivalent
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Syfovre
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the AMD-related geographic atrophy diagnosis and required visual acuity.
    SourceLink
    On This Page
    Coverage CriteriaMedical Benefit CodingAuthorization and Documentation RequirementsTherapy BackgroundPolicy Definitions

    Unsupported block type: documentation

    Denial Risk

    Excluded Clinical Circumstances

    Syfovre is not covered when exclusionary clinical circumstances apply, including ocular or periocular infection, active intraocular inflammation, use outside FDA-approved labeling, or GA caused by a condition other than AMD.

    • Ocular or periocular infections.
    • Active intraocular inflammation.
    • Age, dosage, and/or frequency outside FDA-approved package labeling.
    • GA secondary to a condition other than AMD, such as Stargardt disease in either eye.
    Denial Risk

    Initial Authorization Criteria Not Met

    Initial authorization may be denied when the prescribing or administering provider is not an ophthalmologist, when required medical benefit prior authorization is not obtained, or when the diagnosis, BCVA, or supporting chart-note documentation does not meet the policy criteria.

    • Prescriber and administrator must be an ophthalmologist.
    • Chart notes must confirm GA secondary to AMD.
    • BCVA must meet the required ETDRS or approximate Snellen threshold.
    Denial Risk

    Clinical Benefit Not Documented

    A subsequent authorization may be denied when documentation does not demonstrate that the member has received clinical benefit from Syfovre.

    • Continuation requests require documentation of clinical benefit.
    • Subsequent approvals are for up to 1 year.
    20/320